Molecular Workflow for TB and Rifampicin-Resistance Detection

Purpose

This article explains the molecular workflow behind tuberculosis detection and rifampicin-resistance detection as implemented by the iFIND TBR kit. All parameters are manufacturer-provided and have not been independently verified.

How Molecular TB Detection Works

Molecular TB detection amplifies specific regions of the Mycobacterium tuberculosis genome so that even small amounts of bacterial DNA can be detected. The choice of amplification targets determines what the assay can find: the bacterium itself, drug-resistance mutations, or both.

How the iFIND TBR Kit Works

According to manufacturer documents, the iFIND TBR kit uses three amplification targets:

• IS6110 — an insertion sequence specific to the M. tuberculosis complex. Used to identify the bacterium.
• IS1081 / IS1087 — a second identification target. Manufacturer documents disagree on whether this target is IS1081 or IS1087. This conflict is documented and unresolved.
• rpoB — the gene encoding the beta-subunit of RNA polymerase. Mutations in the rifampicin resistance-determining region (RRDR) of rpoB cause rifampicin resistance.

IS6110

IS6110 is an insertion sequence present in multiple copies in most M. tuberculosis complex strains. It is widely used in TB molecular diagnostics because its specificity for the complex and its multiple copies support both sensitivity and specificity.

IS1081 / IS1087

IS1081 is a well-characterised insertion sequence of the M. tuberculosis complex, present in several copies in the reference genome. IS1087 is a less common designation; it may be a typographical variant, an alternative name, or a distinct element. Because IS1081 and IS1087 may refer to different genetic elements, the choice of target can affect analytical sensitivity, specificity, and comparability with other assays. This conflict requires manufacturer clarification.

rpoB

Rifampicin kills M. tuberculosis by inhibiting RNA polymerase. Mutations in the RRDR of rpoB alter the enzyme so that rifampicin binds less effectively, producing resistance. Detecting these mutations is therefore a molecular proxy for rifampicin resistance.

What Rifampicin Resistance Means Clinically

Rifampicin is a cornerstone of first-line TB treatment. Rifampicin resistance is the principal marker of multidrug-resistant TB (MDR-TB), because in most cases it accompanies isoniazid resistance. Rapid detection of rifampicin resistance allows clinicians to move a patient onto an MDR-TB regimen sooner, which improves outcomes and reduces onward transmission.

Important limitations of molecular rpoB detection:

• Not every mutation in the RRDR produces clinically significant resistance.
• Some resistance-causing mutations fall outside the RRDR and are not detected by standard molecular assays.
• A molecular resistance result should be confirmed phenotypically where possible.

Manufacturer-Provided Performance Parameters

The tenfold difference between the TB-detection LoD (10 CFU/mL) and the resistance-detection LoD (100 CFU/mL) has a practical consequence: a specimen with a bacterial load between 10 and 100 CFU/mL may return a TB-positive but resistance-indeterminate result.

Extending the Workflow with IFQ

After a TBR result, the iFIND IFQ kit can extend the resistance profile to isoniazid (targets katG, inhA) and fluoroquinolones (target gyrA). IFQ does not detect resistance to injectable drugs. The combined TBR + IFQ workflow therefore covers rifampicin, isoniazid, and fluoroquinolones, but not the full second-line injectable panel.

Evidence Boundary

All targets, LoD values, and turnaround times above are manufacturer-provided (evidence level B). No independent peer-reviewed clinical study has been confirmed. The IS1081 / IS1087 conflict and the 85-minute versus 120-minute turnaround-time discrepancy are documented and unresolved. CDSCO registration is not verified.

Important Note

This article describes manufacturer-provided parameters only. No CDSCO registration is claimed. SinoBio Access is not a distributor and does not sell medical devices.